European cancer mortality predictions for the year 2024 with focus on colorectal cancer

Annals of Oncology, Год журнала: 2024, Номер 35(3), С. 308 - 316

Опубликована: Янв. 29, 2024

We predicted cancer mortality figures for 2024 the European Union (EU), its five most populous countries, and UK. focused on from colorectal (CRC).

Язык: Английский

---

GPT-4 for Information Retrieval and Comparison of Medical Oncology Guidelines

NEJM AI, Год журнала: 2024, Номер 1(6)

Опубликована: Май 17, 2024

Oncologists face increasingly complex clinical decision-making processes as new cancer therapies are approved and treatment guidelines revised at an unprecedented rate. With the aim of improving oncologists' efficiency supporting their adherence to most recent recommendations, we evaluated use large language model generative pretrained transformer 4 (GPT-4) interpret from American Society Clinical Oncology European for Medical Oncology. The ability GPT-4 answer clinically relevant questions regarding management patients with pancreatic cancer, metastatic colorectal hepatocellular carcinoma was assessed. We also assessed outputs without retrieval-augmented generation (RAG), which provided additional knowledge model, then manually compared results original guideline documents. RAG correct responses in 84% cases (of 218 statements, 184 were correct, 30 inaccurate, wrong). only 57% 163 93 29 41 showed that GPT-4, when enhanced information through RAG, can accurately identify detailed similarities disparities diagnostic proposals across different authoritative sources.

Язык: Английский

---

REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer

Annals of Surgery, Год журнала: 2024, Номер unknown

Опубликована: Фев. 26, 2024

Objective: The REDISCOVER consensus conference aimed at developing and validate guidelines on the perioperative care of patients with borderline resectable (BR-) locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC). Summary Background Data: Coupled improvements in chemotherapy radiation, contemporary approach to surgery supports resection BR-PDAC and, a lesser extent, LA-PDAC. Guidelines outlining selection for these are lacking. Methods: Scottish Intercollegiate Network (SIGN) methodology was used develop create recommendations. Delphi reach (agreement ≥80%) among experts. Recommendations were approved after debate vote international experts cancer management. A Validation Committee AGREE II-GRS tool assess methodological quality guidelines. Moreover, an independent multidisciplinary advisory group revised statements ensure adherence non-surgical Results: Overall, 34 recommendations created targeting centralization, training, staging, patient surgery, possibility uncommon scenarios, timing avoidance vascular reconstruction, details resection/reconstruction, arterial divestment, frozen section histology perivascular tissue, extent lymphadenectomy, anticoagulation prophylaxis role minimally invasive surgery. level evidence however low 29 clinical questions. Participants agreed that most conducive mean promptly advance our understanding this field is establish registry addressing population (https://rediscover.unipi.it/) Conclusions: provide pertaining pancreatectomy BR- LA-PDAC, serve as basis new population.

Язык: Английский

---

MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomised phase 2 trial

˜The œLancet. Gastroenterology & hepatology, Год журнала: 2024, Номер 9(5), С. 448 - 459

Опубликована: Март 19, 2024

Язык: Английский

---

Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer

JAMA Surgery, Год журнала: 2024, Номер 159(10), С. 1139 - 1139

Опубликована: Июль 24, 2024

There are currently no clinically relevant criteria to predict a futile up-front pancreatectomy in patients with anatomically resectable pancreatic ductal adenocarcinoma.

Язык: Английский

---

Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study

The Lancet Oncology, Год журнала: 2024, Номер 25(7), С. 853 - 864

Опубликована: Июнь 1, 2024

Язык: Английский

---

Stereotactic body radiotherapy for pancreatic cancer – A systematic review of prospective data

Clinical and Translational Radiation Oncology, Год журнала: 2024, Номер 45, С. 100738 - 100738

Опубликована: Янв. 28, 2024

Язык: Английский

---

Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX

JAMA Oncology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 23, 2025

Importance The effect of adjuvant chemotherapy following resection pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX (combination leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin in full or modified dosing) on overall survival (OS) is unclear because current studies do not account for the number cycles regimen. Objective To investigate association with OS, taking into Design, Setting, Participants This retrospective cohort study included patients localized treated 2 to 11 followed by across 48 centers 20 countries from 2010 2018. Patients who died within 3 months surgery were excluded (landmark). Data analyzed February 1 December 31, 2023. Exposures Preoperative eventually chemotherapy. Main Outcomes Measures primary outcome was calculated 3-month landmark. Cox regression analysis, including interaction analyses, performed OS. Results Overall, 767 (median [IQR] age, 62 [55-67] years; 404 [52.7%] male). Adjuvant independently associated prolonged OS (hazard ratio [HR], 0.66; 95% CI, 0.49-0.87), confirmed adjusted curves. analysis assess estimated treatment subgroups statistically significant. forest plot test suggest that lower among receiving 8 more (m)FOLFIRINOX, those had radiological response, ypN0 disease. Compared no chemotherapy, both (HR, 0.57; 0.40-0.80) other multiagent regimens 0.61; 0.41-0.92) whereas single-agent 0.75; 0.55-1.03). Conclusions Relevance In this study, improved not. impact may be such as having ypN0.

Язык: Английский

---

5-Hydroxymethylcytosine modifications in circulating cell-free DNA: frontiers of cancer detection, monitoring, and prognostic evaluation

Biomarker Research, Год журнала: 2025, Номер 13(1)

Опубликована: Март 7, 2025

Abstract Developing accurate, clinically convenient, and non-invasive methods for early cancer detection, monitoring, prognosis assessment is essential improving patient survival rates, enhancing quality of life, reducing the socioeconomic burden associated with cancer. This goal critical in precision oncology. Genetic epigenetic alterations circulating cell-free DNA (cfDNA) have emerged as transformative tools advancing outcomes. Among these, 5-hydroxymethylcytosine (5hmC) modifications cfDNA stand out promising markers, offering insights into initiation, progression, metastasis, across various types, such lung cancer, colorectal hepatocellular carcinoma. review comprehensively explores biology sequencing methodologies 5hmC, emphasizing their potential screening, diagnosis, treatment prognostic assessment. It highlights recent advancements cfDNA-derived 5hmC signatures’ applications, addressing strengths limitations context clinical translation. Furthermore, this outlines key challenges future directions integrating routine practice, facilitating personalized management.

Язык: Английский

---

18F−Prostate−Specific Membrane Antigen PET/CT imaging for potentially resectable pancreatic cancer (PANSCAN−2): a phase I/II study

Cancer Imaging, Год журнала: 2025, Номер 25(1)

Опубликована: Янв. 14, 2025

Abstract Background Current diagnostic imaging modalities have limited ability to differentiate between malignant and benign pancreaticobiliary disease, lack accuracy in detecting lymph node metastases. 18 F-Prostate-Specific Membrane Antigen (PSMA) PET/CT is an modality used for staging of prostate cancer, but has incidentally also identified PSMA-avid pancreatic lesions, histologically characterized as ductal adenocarcinoma (PDAC). This phase I/II study aimed assess the feasibility F-PSMA detect PDAC. Methods Seventeen patients with clinically resectable PDAC underwent prior surgical resection. Images were analyzed both visually (semi)quantitatively by deriving maximum standardized uptake value (SUV max ) tumor-to-background ratio (TBR). TBR was defined SUV primary tumor divided aortic blood pool. Finally, tracer on PET correlated tissue expression PSMA specimens. Results Out 17 scans, 13 scans demonstrated positive uptake, a mean 5.0 ± 1.3. The suspected detectable (TBR ≥ 2) 3.3 For confirmed PDAC, 4.9 1.2 1.5, respectively. Although eight had regional metastases two distant metastases, none these uptake. There no correlation Conclusions able several cancers, including However, generally low, not specific observed or added this setting appears be limited. Trial registration trial registered PANSCAN-2 European Clinical Trials Database (EudraCT number: 2020–002185-14). Graphical

Язык: Английский

---